Aug 15
Opportunity
Flexibility to choose the location for clinical trial procedures (i.e., onsite or offsite [e.g., at home, local clinic, etc.]) can reduce burden on clinical trial participants in terms of travel requirements. Reducing the need to travel to the site for all visits can have a positive impact on recruitment and retention (e.g., giving flexibility around work, childcare, etc.), facilitating participation by individuals located further from clinical sites.
Considerations to Help Action the Opportunity
- Understand conditions that are required for trial conduct and how best to implement them at offsite location(s) to maximize flexibility of participation by utilizing telehealth visits, home nursing, local facilities, mobile clinics, pharmacies, satellite sites, etc.
- Define how study assessments can be performed with the consistency to clinical trial standard, such as:
- Processes to implement protocol (e.g., teach-back technique, real-time monitoring of assessment completion, etc.)
- Safeguards to help confirm that equipment will work correctly (e.g., calibrated equipment, internet access, back-up options, etc.)
- Access to resources in case of emergencies or to help maintain participant safety (e.g., home nurse training, emergency medication, proximity to emergency care facilities, etc.)
- Understand that some visits can be onsite if required, for example, if IMP stability / preparation requirements do not allow for home administration or a physician needs to physically see the participant
- Understand the amount of time procedures take and associated travel time to and from clinics (e.g., travel time could be reduced by offering local lab visits and / or remote visits)
- Partner with investigative sites to leverage their own resources and processes, as applicable, to facilitate offsite visits, and to understand and mitigate challenges / concerns associated with third-party, such as:
- PI accountability and oversight
- Plan for alternative / backup in case of required / requested changes (e.g., independent providers that carry out procedures who are not directly controlled by the sponsor or investigative site including PI oversight) and participant oversight
- Define data delivery plan / map to support compilation of data from various locations / care delivery settings
Value and Potential Benefits
- Brings the clinical trial closer to participants that live far away from the clinic or when clinic visits are logistically complicated to arrange based on personal circumstances (e.g., patient mobility, desire to travel)
- Increases convenience to participate by accommodating various options for the delivery of care
- Allows for flexibility for site staff (e.g., focus on difficult visits vs. simple blood draws) to utilize their time more efficiently and potentially reduces the need for additional operating hours (e.g., weekend and evening visits)
- Potentially allows sites to conduct more clinical trials (e.g., less on-site visits may result in more availability to run trials)
Related Blog Posts
Why the biggest gains in clinical R&D won’t come from technology
Every few years, the clinical research industry rallies around a new wave of innovation. From decentralised trials and digital biomarkers to AI driven automation, each wave brings genuine capability andpromise. Read the full article featuring Kelsey Jakee on page 38 here.
Enough, already: the problem with clinical trial data collection
The clinical research ecosystem has never been more technologically capable — or more burdened by its own ambition. In December 2025, the Tufts Center for the Study of Drug Development and our team at TransCelerate published research that suggests nearly 30% of the data collected in clinical trials do not directly inform key decisions, yet patients are…
2026 DIA Global Annual Meeting: What the FDA’s Real-Time Data Push Actually Means for Sponsors and CROs
In this video interview from the 2026 DIA Global Annual Meeting, Kevin Bugin, head of global regulatory policy and intelligence at Amgen and executive sponsor of TransCelerate’s Embedded Pragmatic Trials initiative, reframes the FDA’s continuous review expectations around real-time evidence generation and explains why quality by design—not data cleanup—is what regulators are now demanding. Watch…
